China SXT Pharmaceuticals (China SXT Pharmaceuticals) Change In Payables And Accrued Expense : $-0.06 Mil (TTM As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is China SXT Pharmaceuticals Change In Payables And Accrued Expense?

China SXT Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2023 was $0.33 Mil. It means China SXT Pharmaceuticals's Accounts Payable & Accrued Expense increased by $0.33 Mil from Mar. 2023 to Sep. 2023 .

China SXT Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Mar. 2023 was $-0.01 Mil. It means China SXT Pharmaceuticals's Accounts Payable & Accrued Expense declined by $0.01 Mil from Mar. 2022 to Mar. 2023 .

China SXT Pharmaceuticals Change In Payables And Accrued Expense Historical Data

The historical data trend for China SXT Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China SXT Pharmaceuticals Change In Payables And Accrued Expense Chart

China SXT Pharmaceuticals Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-0.01

1.89

-0.04

0.33

-0.01

China SXT Pharmaceuticals Semi-Annual Data
	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial									0.28	0.05	0.37	-0.38	0.33

China SXT Pharmaceuticals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.06 Mil.

China SXT Pharmaceuticals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of China SXT Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

China SXT Pharmaceuticals (China SXT Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China SXT Pharmaceuticals Inc (NAS:SXTC) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

2RY0:Germany

Address

No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300

Website

http://www.sxtchina.com

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, Advanced TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates a majority of its revenue from the People's Republic of China.